KR102611611B1 - Pharmaceutical composition containing platycodin D extracted from Platycodon grandiflorum and a method of producting thereof - Google Patents
Pharmaceutical composition containing platycodin D extracted from Platycodon grandiflorum and a method of producting thereof Download PDFInfo
- Publication number
- KR102611611B1 KR102611611B1 KR1020230036774A KR20230036774A KR102611611B1 KR 102611611 B1 KR102611611 B1 KR 102611611B1 KR 1020230036774 A KR1020230036774 A KR 1020230036774A KR 20230036774 A KR20230036774 A KR 20230036774A KR 102611611 B1 KR102611611 B1 KR 102611611B1
- Authority
- KR
- South Korea
- Prior art keywords
- bellflower
- saponin
- pharmaceutical composition
- composition containing
- extract
- Prior art date
Links
- GWBIYORWNUYYMZ-UHFFFAOYSA-N platycodin D Natural products CC1OC(OC2C(O)C(O)COC2OC(=O)C34CCC(C)(C)CC3C5=CCC6C7(C)CC(O)C(OC8CC(CO)C(O)C(O)C8O)C(CO)(CO)C7CCC6(C)C5(C)CC4O)C(O)C(O)C1OC9OCC(O)C(OC%10OCC(O)(CO)C%10O)C9O GWBIYORWNUYYMZ-UHFFFAOYSA-N 0.000 title claims abstract description 27
- CYBWUNOAQPMRBA-NDTOZIJESA-N platycodin D Chemical compound O([C@H]1[C@@H](O)C[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2C1(CO)CO)O)C(=O)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@H]([C@@H]([C@@H](O)[C@H]1O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@](O)(CO)CO2)O)[C@H](O)CO1)O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CYBWUNOAQPMRBA-NDTOZIJESA-N 0.000 title claims abstract description 27
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 23
- 238000000034 method Methods 0.000 title claims abstract description 22
- 235000006753 Platycodon grandiflorum Nutrition 0.000 title description 2
- 244000274050 Platycodon grandiflorum Species 0.000 title 1
- 241000332371 Abutilon x hybridum Species 0.000 claims abstract description 124
- 229930182490 saponin Natural products 0.000 claims abstract description 57
- 150000007949 saponins Chemical class 0.000 claims abstract description 55
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims abstract description 52
- 239000012141 concentrate Substances 0.000 claims abstract description 43
- 239000000284 extract Substances 0.000 claims abstract description 43
- 239000012528 membrane Substances 0.000 claims abstract description 35
- 238000004519 manufacturing process Methods 0.000 claims abstract description 24
- 238000000108 ultra-filtration Methods 0.000 claims abstract description 23
- 239000000843 powder Substances 0.000 claims description 28
- APTNOIWSCDBIAS-UHFFFAOYSA-N 5,10,11-trihydroxy-9,9-bis(hydroxymethyl)-2,2,6a,6b,12a-pentamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid Chemical compound C1C(O)C(O)C(CO)(CO)C2CCC3(C)C4(C)CC(O)C5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C APTNOIWSCDBIAS-UHFFFAOYSA-N 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 239000000126 substance Substances 0.000 claims description 19
- 239000002904 solvent Substances 0.000 claims description 15
- 244000005700 microbiome Species 0.000 claims description 13
- 230000008569 process Effects 0.000 claims description 13
- 229920002521 macromolecule Polymers 0.000 claims description 11
- 239000003960 organic solvent Substances 0.000 claims description 11
- DSHSDWSTXKYPEQ-DAANLMTCSA-N [(2s,3r,4s,5s)-3-[(2s,3r,4s,5r,6s)-5-[(2s,3r,4s,5r)-4-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-4,5-dihydroxyoxan-2-yl] (4ar,5r,6ar,6as,6br,8ar,9r,10r,11s,12ar,14bs)-10-[(2r,3 Polymers O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@@H](O)C[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2[C@@]1(CO)C)O)C(=O)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@H]([C@@H]([C@@H](O)[C@H]1O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@](O)(CO)CO2)O)[C@H](O)CO1)O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DSHSDWSTXKYPEQ-DAANLMTCSA-N 0.000 claims description 10
- DSHSDWSTXKYPEQ-UDVDIBAVSA-N polygalacin D2 Polymers O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@@H](O)C[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2[C@]1(CO)C)O)C(=O)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@H]([C@@H]([C@@H](O)[C@H]1O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@](O)(CO)CO2)O)[C@H](O)CO1)O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DSHSDWSTXKYPEQ-UDVDIBAVSA-N 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- HFNGSIBHHMFWQB-UHFFFAOYSA-N Platycogenic acid A Natural products C1C(O)C(O)C(CO)(C(O)=O)C2CCC3(C)C4(C)CC(O)C5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C HFNGSIBHHMFWQB-UHFFFAOYSA-N 0.000 claims description 8
- 150000002596 lactones Chemical class 0.000 claims description 8
- 239000005913 Maltodextrin Substances 0.000 claims description 6
- 229920002774 Maltodextrin Polymers 0.000 claims description 6
- 229940035034 maltodextrin Drugs 0.000 claims description 6
- MMBAMPXMNQQFQO-UHFFFAOYSA-N platyconic acid A Natural products OC1C(O)C(OC2C(C(OC3C(C(O)(CO)CO3)O)C(O)CO2)O)C(C)OC1OC1C(O)C(O)COC1OC(=O)C1(C(CC2(C)C3(C)CCC4C5(CO)C(O)=O)O)CCC(C)(C)CC1C2=CCC3C4(C)CC(O)C5OC1OC(CO)C(O)C(O)C1O MMBAMPXMNQQFQO-UHFFFAOYSA-N 0.000 claims description 6
- -1 Platyconic acid A methyl ester Chemical class 0.000 claims description 5
- JINCXMJGROALLO-UHFFFAOYSA-N Deapio-platycodin D Natural products CC1OC(OC2C(O)C(O)COC2OC(=O)C34CCC(C)(C)CC3C5=CCC6C7(C)CC(O)C(OC8CC(CO)C(O)C(O)C8O)C(CO)(CO)C7CCC6(C)C5(C)CC4O)C(O)C(O)C1OC9OCC(O)C(O)C9O JINCXMJGROALLO-UHFFFAOYSA-N 0.000 claims description 4
- BDCUGHMNUOTFKX-YJGMJMKZSA-N [(2s,3r,4s,5s)-3-[(2s,3r,4s,5r,6s)-5-[(2s,3r,4s,5r)-4-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-4,5-dihydroxyoxan-2-yl] (4ar,5r,6ar,6as,6br,8ar,9r,10r,11s,12ar,14bs)-5,11-dihy Polymers O([C@H]1[C@@H](O)C[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2[C@@]1(CO)C)O)C(=O)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@H]([C@@H]([C@@H](O)[C@H]1O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@](O)(CO)CO2)O)[C@H](O)CO1)O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O BDCUGHMNUOTFKX-YJGMJMKZSA-N 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- HCKUIVZXCXTBEH-PSRBGVDOSA-N deapio-platycodin D Chemical compound O([C@H]1[C@@H](O)C[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2C1(CO)CO)O)C(=O)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@H]([C@@H]([C@@H](O)[C@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)CO1)O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HCKUIVZXCXTBEH-PSRBGVDOSA-N 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- BDCUGHMNUOTFKX-DDRWPPTGSA-N polygalacin D Polymers O([C@H]1[C@@H](O)C[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2[C@]1(CO)C)O)C(=O)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@H]([C@@H]([C@@H](O)[C@H]1O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@](O)(CO)CO2)O)[C@H](O)CO1)O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O BDCUGHMNUOTFKX-DDRWPPTGSA-N 0.000 claims description 4
- DJPJACADAIGMKF-CTELNEMLSA-N polygalacin-D Natural products O=C(O[C@H]1[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O[C@@]4(O)[C@H](O)[C@@](O)(CO)CO4)[C@H](O)CO3)[C@H](C)O2)[C@@H](O)[C@@H](O)CO1)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)[C@@H]([C@]5(C)[C@H]([C@@](CO)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O)C5)CC4)CC=C3[C@@H]1CC(C)(C)CC2 DJPJACADAIGMKF-CTELNEMLSA-N 0.000 claims description 4
- DSHSDWSTXKYPEQ-UHFFFAOYSA-N polygalacin-D2 Natural products OC1C(O)C(OC2C(C(OC3C(C(O)(CO)CO3)O)C(O)CO2)O)C(C)OC1OC1C(O)C(O)COC1OC(=O)C1(C(CC2(C)C3(C)CCC4C5(CO)C)O)CCC(C)(C)CC1C2=CCC3C4(C)CC(O)C5OC(C1O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O DSHSDWSTXKYPEQ-UHFFFAOYSA-N 0.000 claims description 4
- 239000011148 porous material Substances 0.000 claims description 4
- PXQNZQURQNZGKZ-UHFFFAOYSA-N 3-O-beta-Laminaribiosyl-platycodin-D(2) Natural products OC1C(O)C(OC2C(C(OC3C(C(O)(CO)CO3)O)C(O)CO2)O)C(C)OC1OC1C(O)C(O)COC1OC(=O)C1(C(CC2(C)C3(C)CCC4C5(CO)CO)O)CCC(C)(C)CC1C2=CCC3C4(C)CC(O)C5OC(C1O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O PXQNZQURQNZGKZ-UHFFFAOYSA-N 0.000 claims description 3
- XHKCYIRZWRRXNG-UHFFFAOYSA-N Platycodin D3 Natural products OC1C(O)C(OC2C(C(OC3C(C(O)(CO)CO3)O)C(O)CO2)O)C(C)OC1OC1C(O)C(O)COC1OC(=O)C1(C(CC2(C)C3(C)CCC4C5(CO)CO)O)CCC(C)(C)CC1C2=CCC3C4(C)CC(O)C5OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C(O)C1O XHKCYIRZWRRXNG-UHFFFAOYSA-N 0.000 claims description 3
- MMBAMPXMNQQFQO-JQIGHYGPSA-N Platyconic acid A Chemical compound O([C@H]1[C@@H](O)C[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2[C@@]1(CO)C(O)=O)O)C(=O)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@H]([C@@H]([C@@H](O)[C@H]1O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@](O)(CO)CO2)O)[C@H](O)CO1)O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O MMBAMPXMNQQFQO-JQIGHYGPSA-N 0.000 claims description 3
- KGGGRGBDMBZXKF-UHFFFAOYSA-N Virganreagenin G Natural products C1C(O)C(O)C(C)(CO)C2CCC3(C)C4(C)CC(O)C5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C KGGGRGBDMBZXKF-UHFFFAOYSA-N 0.000 claims description 3
- 239000007799 cork Substances 0.000 claims description 3
- WHADRFMYRLBVAJ-BCXQWGEVSA-N deapio-platycodin D2 Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@@H](O)C[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2C1(CO)CO)O)C(=O)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@H]([C@@H]([C@@H](O)[C@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)CO1)O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O WHADRFMYRLBVAJ-BCXQWGEVSA-N 0.000 claims description 3
- QDTKFVBGHXCISC-UHFFFAOYSA-N deapioplatycodin-D2 Natural products OC1C(O)C(OC2C(C(O)C(O)CO2)O)C(C)OC1OC1C(O)C(O)COC1OC(=O)C1(C(CC2(C)C3(C)CCC4C5(CO)CO)O)CCC(C)(C)CC1C2=CCC3C4(C)CC(O)C5OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C(O)C1O QDTKFVBGHXCISC-UHFFFAOYSA-N 0.000 claims description 3
- UTBMWMLXRNXHHQ-ONYRRNLVSA-N deapioplatycoside E Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@H]1[C@@H](O)C[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2C1(CO)CO)O)C(=O)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@H]([C@@H]([C@@H](O)[C@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)CO1)O)C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UTBMWMLXRNXHHQ-ONYRRNLVSA-N 0.000 claims description 3
- PXQNZQURQNZGKZ-MXNHKPIDSA-N platycodin D2 Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@@H](O)C[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2C1(CO)CO)O)C(=O)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@H]([C@@H]([C@@H](O)[C@H]1O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@](O)(CO)CO2)O)[C@H](O)CO1)O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PXQNZQURQNZGKZ-MXNHKPIDSA-N 0.000 claims description 3
- XHKCYIRZWRRXNG-COMVGSAYSA-N platycodin D3 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@H]1[C@@H](O)C[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2C1(CO)CO)O)C(=O)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@H]([C@@H]([C@@H](O)[C@H]1O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@](O)(CO)CO2)O)[C@H](O)CO1)O)C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XHKCYIRZWRRXNG-COMVGSAYSA-N 0.000 claims description 3
- TZSYJZBVJYXHEK-SNQGWRGYSA-N platycoside E Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@H]1[C@@H](O)C[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2C1(CO)CO)O)C(=O)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@H]([C@@H]([C@@H](O)[C@H]1O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@](O)(CO)CO2)O)[C@H](O)CO1)O)C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O TZSYJZBVJYXHEK-SNQGWRGYSA-N 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 13
- 230000001093 anti-cancer Effects 0.000 abstract description 4
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 4
- 230000036407 pain Effects 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 2
- 235000017709 saponins Nutrition 0.000 description 44
- 238000001914 filtration Methods 0.000 description 12
- 235000000346 sugar Nutrition 0.000 description 12
- 238000000605 extraction Methods 0.000 description 11
- 230000000144 pharmacologic effect Effects 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 150000008163 sugars Chemical class 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 235000013376 functional food Nutrition 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 238000001694 spray drying Methods 0.000 description 5
- 230000003579 anti-obesity Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000006909 anti-apoptosis Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 102000038379 digestive enzymes Human genes 0.000 description 2
- 108091007734 digestive enzymes Proteins 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000012465 retentate Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 150000004043 trisaccharides Chemical class 0.000 description 2
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 1
- CNHZRRBWLMSLDX-WNHLAMKZSA-N 2''O-acetylplatycodin D Chemical compound O([C@H]1[C@@H](O)C[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2C1(CO)CO)O)C(=O)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@H]([C@@H]([C@@H](O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@](O)(CO)CO2)O)[C@H](O)CO1)O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CNHZRRBWLMSLDX-WNHLAMKZSA-N 0.000 description 1
- HCXVJBMSMIARIN-ZETWWWAOSA-N 24alpha-Ethyl-koprostanol Natural products CC[C@H](C=C[C@H](C)[C@H]1CC[C@@H]2[C@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C)C(C)C HCXVJBMSMIARIN-ZETWWWAOSA-N 0.000 description 1
- ODEHMIGXGLNAKK-OESPXIITSA-N 6-kestotriose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 ODEHMIGXGLNAKK-OESPXIITSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 102000017946 PGC-1 Human genes 0.000 description 1
- 108700038399 PGC-1 Proteins 0.000 description 1
- 241000357613 Platycodon Species 0.000 description 1
- 235000006751 Platycodon Nutrition 0.000 description 1
- 240000003582 Platycodon grandiflorus Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- JZVFJDZBLUFKCA-FXIAWGAOSA-N alpha-Spinasterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)CC[C@H]33)C)C3=CC[C@H]21 JZVFJDZBLUFKCA-FXIAWGAOSA-N 0.000 description 1
- JZVFJDZBLUFKCA-UTQQLQBSSA-N alpha-spinasterol Natural products CC[C@H](C=C[C@H](C)[C@H]1CC[C@H]2C3=CC[C@@H]4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C JZVFJDZBLUFKCA-UTQQLQBSSA-N 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- OQMZNAMGEHIHNN-CIFIHVIMSA-N delta7-stigmasterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)CC[C@H]33)C)C3=CC=C21 OQMZNAMGEHIHNN-CIFIHVIMSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- IVDSKBGNLNNRFN-UHFFFAOYSA-N platycodin A Natural products CC1OC(OC2C(O)C(O)COC2OC(=O)C34CCC(C)(C)CC3C5=CCC6C7(C)CC(O)C(OC8CC(CO)C(O)C(O)C8O)C(CO)(CO)C7CCC6(C)C5(C)CC4O)C(OC(=O)C)C(O)C1OC9OCC(O)C(OC%10OCC(O)(CO)C%10O)C9O IVDSKBGNLNNRFN-UHFFFAOYSA-N 0.000 description 1
- 229930189914 platycodon Natural products 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
본 발명은 도라지에서 추출된 도라지 사포닌 농축물을 함유하는 약학적 조성물의 제조방법에 관한 것으로서, 보다 상세하게는 도라지 뿌리의 피층으로부터 추출한 플라티코딘 D가 다량으로 함유된 약학적 조성물을 생성하여 항염증, 항암, 통증완화 효과 등이 우수한 약제를 제조할 수 있도록 하는 도라지에서 추출된 도라지 사포닌 농축물을 함유하는 약학적 조성물의 제조방법에 관한 것이다.
본 발명에 따르면 도라지 뿌리로부터 도라지 사포닌을 다량 함유한 추출물을 수득하고, 이 수득된 추출물로부터 2종 이상의 한외 여과막을 이용하여 여과를 함으로써 미생물학적으로 위생적이며, 특히 플라티코딘 D의 함유량을 증가시킨 도라지 사포닌을 농축 생산할 수 있는 효과가 있다.The present invention relates to a method for producing a pharmaceutical composition containing bellflower saponin concentrate extracted from bellflower root, and more specifically, to produce a pharmaceutical composition containing a large amount of platycodin D extracted from the cortex of bellflower root, It relates to a method for manufacturing a pharmaceutical composition containing bellflower saponin concentrate extracted from bellflower root, which allows the manufacture of a medicine with excellent anti-inflammatory, anticancer, and pain relieving effects.
According to the present invention, an extract containing a large amount of bellflower saponin is obtained from bellflower roots, and the obtained extract is filtered using two or more types of ultrafiltration membranes, thereby making it microbiologically hygienic and especially increasing the content of platycodin D. It is effective in producing concentrated bellflower saponin.
Description
본 발명은 도라지에서 추출된 도라지 사포닌 농축물을 함유하는 약학적 조성물의 제조방법에 관한 것으로서, 보다 상세하게는 도라지 뿌리의 피층으로부터 추출한 플라티코딘 D가 다량으로 함유된 약학적 조성물을 생성하여 항염증, 항암, 통증완화 효과 등이 우수한 약제를 제조할 수 있도록 하는 도라지에서 추출된 도라지 사포닌 농축물을 함유하는 약학적 조성물의 제조방법에 관한 것이다.The present invention relates to a method for producing a pharmaceutical composition containing bellflower saponin concentrate extracted from bellflower root, and more specifically, to produce a pharmaceutical composition containing a large amount of platycodin D extracted from the cortex of bellflower root, It relates to a method for manufacturing a pharmaceutical composition containing bellflower saponin concentrate extracted from bellflower root, which allows the manufacture of a medicine with excellent anti-inflammatory, anticancer, and pain relieving effects.
도라지(Platycodon grandiforumA. DC)는 동아시아 지역에 자생 또는 재배되는 초롱꽃과(Campanualaceae)에 속하는 다년생 초본류로서, 주로 뿌리가 전통적인 생약재 및 식품으로 활용되고 있다.Bellflower ( Platycodon grandiforum A. DC) is a perennial herb belonging to the Campanualaceae family that grows or is cultivated in East Asia, and its roots are mainly used as traditional herbal medicine and food.
도라지의 주 함유성분으로는 탄수화물(당)이 90% 이상을 차지하고, 그 외 단백질, 지방, 회분 등이 있다. 탄수화물은 포도당, 과당, 설탕, 케스토스 등 이당류 혹은 삼당류가 대부분을 차지하고, 이눌린(inulin), 플라티코디닌(platycodinin ; 과당 10분자 정도의 다당류) 등의 다당류가 보고되고 있다. 그 외에 트리테르페노이드사포닌(triterpenoid saponin)[플라티코딘(platycodin) A, C, D, D2, 폴리갈라신(polygalacin) D, D2 등 24 종류가 보고되고 있음] 약 2% 정도 존재하고 있는데, 이들 사포닌 성분들은 도라지의 다양한 약리효능의 유효성분으로 주목받고 있다.The main components of bellflower root include carbohydrates (sugar), which accounts for more than 90%, and other ingredients include protein, fat, and ash. Carbohydrates are mostly disaccharides or trisaccharides such as glucose, fructose, sucrose, and kestose, and polysaccharides such as inulin and platycodinin (a polysaccharide of about 10 fructose molecules) have been reported. In addition, triterpenoid saponins (24 types including platycodin A, C, D, D2, polygalacin D, D2, etc. have been reported) exist at about 2%. , these saponin components are attracting attention as active ingredients for various medicinal effects of bellflower root.
그 밖에도 도라지에는 α-스피나스테롤(α-spinasterol), Δ7-스티그마스테롤(Δ7-stigmasterol), α-스피나스테릴-β-D-글루코사이드(α-spinasteryl-β-D-glucoside) 등 스테로이드(steroid) 화합물이 약 0.03 % 정도 함유되어 있다.In addition, bellflower root contains steroids such as α-spinasterol, Δ7-stigmasterol, and α-spinasteryl-β-D-glucoside. It contains approximately 0.03% of (steroid) compounds.
도라지는 주로 거담, 진해작용, 기침 및 기관지염의 치료제로 사용되어 왔으며, 항염증 효과[참고: Biol. Pharm, Bull., 11, p.2114, 2008; Eur. J. Pharmacol., 537, p.1, 2006; Life sci., 76, p.2315, 2005], 항암 효과[Int. J.Cancer, 261, p.2674, 2008; Cancer Lett., 261, p.98, 2008], 통증완화효과[참고: Am.J. Chin. Med., 32, p.257, 2004; Planta Med., 68, p.794, 2002], 소화효소분비 억제효과[참고 : Arch.Pharm. Res., 27, p.1048, 2004], 콜레스테롤 대사 개선효과[Eur. J. Pharmacol., 537, p.1, 2006; J.Food Sci., 73, p.195, 2008], 간기능 보호 및 개선 효과[Lee, K..J. et. al., Toxicol. Lett. 147, 271-282, 2004 ; Food and Chemical Toxicology, 47, 2749~2754, 2009 ; Ann Nutri Metab 58, 224~231, 2011], 면역기능 조절 활성 효과[Ahn, K.S. et al., Life Sci. 76, 2315-2328, 2005] 등의 약리효능이 있는 것으로 알려져 있다.Bellflower root has been mainly used as an expectorant, antitussive, and treatment for cough and bronchitis, and has anti-inflammatory effects [Reference: Biol. Pharm, Bull., 11, p.2114, 2008; Eur. J. Pharmacol., 537, p.1, 2006; Life sci., 76, p.2315, 2005], anticancer effect [Int. J. Cancer, 261, p.2674, 2008; Cancer Lett., 261, p.98, 2008], pain relief effect [Reference: Am.J. Chin. Med., 32, p.257, 2004; Planta Med., 68, p.794, 2002], digestive enzyme secretion inhibitory effect [Reference: Arch.Pharm. Res., 27, p.1048, 2004], cholesterol metabolism improvement effect [Eur. J. Pharmacol., 537, p.1, 2006; J.Food Sci., 73, p.195, 2008], liver function protection and improvement effect [Lee, K..J. et. al., Toxicol. Lett. 147, 271-282, 2004 ; Food and Chemical Toxicology, 47, 2749~2754, 2009; Ann Nutri Metab 58, 224~231, 2011], immune function regulation activity effect [Ahn, K.S. et al., Life Sci. 76, 2315-2328, 2005] is known to have pharmacological effects.
또한 뇌신경세포 보호 효과[Yoo Ki-Yeon etal., Neurosci. lett. 444(1), 97-101 (2008)], 항비만 효과[Zhao, H. L. et al., J. Food. Sci.73(8), H195-H200, (2008)] 등이 보고되고 있다. 특히, 플라티코딘 D는 길경(도라지의 뿌리로 만든 약재)의 주요 약리성분을 가지는 사포닌으로서, 항세포사멸(anti-apoptosis, 대한민국 특허등록 제10-0564927호), 항비만(anti-obesity, 대한민국 특허등록 제10-0750333호), 항염증(anti-inflammation, 대한민국 특허등록 제10-0696647호)의 효능이 알려져 있어, 약물학적 가치가 큰 단일성분(Hahn J., Nutr., 130, p.2760, 2000)으로 알려져 있다.Additionally, it has a protective effect on brain nerve cells [Yoo Ki-Yeon et al., Neurosci. lett. 444(1), 97-101 (2008)], anti-obesity effect [Zhao, H. L. et al., J. Food. Sci.73(8), H195-H200, (2008)], etc. have been reported. In particular, platycodin D is a saponin that has the main pharmacological properties of Gilgyeong (a herb made from the roots of bellflower root), and has anti-apoptosis (Korean Patent Registration No. 10-0564927), anti-obesity, and anti-obesity properties. A single ingredient with great pharmacological value (Hahn J., Nutr., 130, p. .2760, 2000).
이와 같은 천연물로부터의 약리활성을 나타내는 화합물들을 효율적으로 분리하기 위하여 많은 연구자들이 이들의 추출, 분리, 정제 과정에 대한 여러 방법들을 개발, 보고하고 있는 실정이다.In order to efficiently isolate compounds showing pharmacological activity from such natural products, many researchers are developing and reporting various methods for their extraction, separation, and purification processes.
일반적으로 천연물 성분 분리는 여러 종류의 고체 정치상과 액체 이동상을 이용한 칼럼 크로마토그래피법을 이용하고 있다. 그러나 이 방법은 한 번에 분리할 수 있는 양에 제한이 있고, 장비의 가격과 고체 정지상의 주기적인 교체의 이유로 분리 양에 비해 비용이 많이 들어 대량 분리, 생산 방식의 공업화에 어려움이 있다.In general, column chromatography using various types of solid stationary phases and liquid mobile phases is used to separate natural product components. However, this method is limited in the amount that can be separated at one time, and due to the price of the equipment and periodic replacement of the solid stationary phase, the cost is high compared to the amount of separation, making it difficult to industrialize large-scale separation and production methods.
[참고문헌 1] Yoo Ki-Yeon. et al., Neurosci. lett. 444([0011] 1), 97-101, (2008)[Reference 1] Yoo Ki-Yeon. et al., Neurosci. lett. 444([0011] 1), 97-101, (2008)
[참고문헌 2] Zhao, H. L. et al., J. Food Sci. 73(8), H195-H200, (2008)[Reference 2] Zhao, H. L. et al., J. Food Sci. 73(8), H195-H200, (2008)
[참고문헌 3] Lee, K. J. et al., Toxicol. Lett. 147, 271-282, (2004)[Reference 3] Lee, K. J. et al., Toxicol. Lett. 147, 271-282, (2004)
[참고문헌 4] Ahn, K. S. et al., Life Sci. 76, 2315-2328, (2005)[Reference 4] Ahn, K. S. et al., Life Sci. 76, 2315-2328, (2005)
[참고문헌 5] Lee, K. J. et al., Food Chem. Toxicol. 47, 2749~2754, (2009)[Reference 5] Lee, K. J. et al., Food Chem. Toxicol. 47, 2749~2754, (2009)
[참고문헌 6] Zhang, L. et al., Molecules 12(4), 832-841, (2007)[Reference 6] Zhang, L. et al., Molecules 12(4), 832-841, (2007)
전술한 문제점을 해결하기 위한 본 발명은 물과 유기용매의 적절한 배합으로 도라지 사포닌의 추출량을 극대화하여 대량으로 추출하고, 이들 추출물에서부터 한외여과막을 이용하여 플라티코딘 D를 다량으로 함유하는 도라지 사포닌을 대량으로 농축할 수 있도록 하는 도라지에서 추출된 도라지 사포닌 농축물을 함유하는 약학적 조성물의 제조방법을 제공하는 것을 목적으로 한다.In order to solve the above-mentioned problems, the present invention maximizes the extraction amount of bellflower saponins by appropriately mixing water and organic solvents, extracts them in large quantities, and extracts bellflower saponins containing a large amount of platycodin D from these extracts using an ultrafiltration membrane. The purpose is to provide a method for producing a pharmaceutical composition containing bellflower saponin concentrate extracted from bellflower root, which allows concentration in large quantities.
또한 도라지로부터 플라티코딘 D를 다량으로 함유하는 도라지 사포닌을 간단하고 경제적인 방법으로 단시간에 수득하고, 약리효과를 극대화할 수 있는 농도로 농축할 수 있도록 하는 도라지에서 추출된 도라지 사포닌 농축물을 함유하는 약학적 조성물의 제조방법을 제공하는 것을 목적으로 한다.In addition, it contains bellflower saponin concentrate extracted from bellflower root, which allows bellflower saponin, which contains a large amount of platycodin D, to be obtained in a simple and economical way in a short time and concentrated to a concentration that can maximize the pharmacological effect. The purpose is to provide a method for manufacturing a pharmaceutical composition.
전술한 문제점을 해결하기 위해 안출된 본 발명은 도라지 사포닌 농축물을 함유하는 약학적 조성물의 제조방법으로써, 도라지 뿌리 중에서 코르크층으로 형성된 피층을 건조시키고 분쇄하여 분말 상태로 준비하는 제1단계와; 도라지 분말에 물, 유기용매, 물과 유기용매의 혼합물 중 어느 하나로 이루어진 용매를 투입하여 도라지 추출물을 생성하는 제2단계와; 상기 도라지 추출물을 냉각시키는 제3단계와; 상기 도라지 추출물을 마이크로필터를 통과시켜 불용성 물질을 제거하는 제4단계와; 상기 불용성 물질이 제거된 도라지 추출물을 분자량 한계가 20,000 이상인 제1 한외 여과막을 통과시켜 미생물 및 거대 분자를 제거하는 제5단계와; 상기 미생물과 거대분자가 제거된 추출물을 분자량 한계가 1,000 이상인 제2 한외 여과막을 통과시켜 저분자물질과 물을 제거하여 도라지 사포닌 농축물을 생성하는 제6단계와; 상기 도라지 사포닌 농축물을 60℃ 내지 80℃의 범위에서 감압 가열하여 농축시키는 제7단계와; 상기 도라지 사포닌 농축물을 건조하여 분말로 만들고, 상기 분말이 함유된 약학적 조성물을 제조하는 제8단계;를 포함한다.The present invention, which was devised to solve the above-mentioned problems, is a method for producing a pharmaceutical composition containing bellflower saponin concentrate, comprising: a first step of drying and pulverizing the cork layer of the bellflower root to prepare it in powder form; A second step of producing a bellflower extract by adding a solvent consisting of water, an organic solvent, or a mixture of water and an organic solvent to the bellflower root powder; A third step of cooling the bellflower extract; A fourth step of passing the bellflower extract through a microfilter to remove insoluble substances; A fifth step of removing microorganisms and macromolecules by passing the bellflower extract from which the insoluble substances have been removed through a first ultrafiltration membrane with a molecular weight limit of 20,000 or more; A sixth step of passing the extract from which the microorganisms and macromolecules have been removed through a second ultrafiltration membrane with a molecular weight limit of 1,000 or more to remove low molecular substances and water to produce a bellflower saponin concentrate; A seventh step of concentrating the bellflower saponin concentrate by heating it under reduced pressure in the range of 60°C to 80°C; An eighth step of drying the bellflower saponin concentrate into powder and preparing a pharmaceutical composition containing the powder is included.
상기 도라지 사포닌 농축물에는 데아피오플라티코사이드 E(Deapioplatycoside E), 플라티코사이드 E(Platycoside E), 플라티코딘 D3(Platycodin D3), 폴리갈라신 D2(Polygalacin D2), 폴리갈라신 D(Polygalacin D), 플라티콘산 A(Platyconic acid A), 데아피오플라티코딘 D2(Deapioplatycodin D2), 플라티코딘 D2(Platycodin D2), 데아피오플라티코딘 D(Deapioplatycodin D), 플라티코딘 D(Platycodin D), 2"-O-아세틸-데아피오폴리갈라신 D2(2"-O-acetyl-deapiopolygalacin D2), 2"-O-아세틸-폴리갈라신 D2(2"-O-acetyl-polygalacin D2) 및 플라티콘산 A 메틸에스테르(Platyconic acid A methyl ester), 플라티코디게닌(Platycodigenin), 폴리갈라신산(Polygalacic acid), 플라티코게닌산 A 락톤(Platycogenic acid A lactone), 플라티코게닌산 A 락톤 3-O-글루코피라노사이드(Platycogenic acid A lactone 3-O-glucopyranoside), 플라티코디게닌 3-O-글루코피라노사이드 28-메틸에스테르(Platycodigenin 3-O-glucopyranoside 28-methyl ester) 및 플라티코디게닌 3-O-라미나리비오사이드 28-메틸에스테르(Platycodigenin 3-O-laminaribioside 28-methyl ester) 중의 하나 이상의 사포닌계 화합물이 함유되는 것을 특징으로 한다.The bellflower saponin concentrate includes Deapioplatycoside E, Platycoside E, Platycodin D3, Polygalacin D2, and Polygalacin D. D), Platyconic acid A, Deapioplatycodin D2, Platycodin D2, Deapioplatycodin D, Platycodin D D), 2"-O-acetyl-deapiopolygalacin D2 (2"-O-acetyl-deapiopolygalacin D2), 2"-O-acetyl-polygalacin D2 (2"-O-acetyl-polygalacin D2) and Platyconic acid A methyl ester, Platycodigenin, Polygalacic acid, Platycogenic acid A lactone, Platycogenic acid A lactone. 3-O-glucopyranoside (Platycogenic acid A lactone 3-O-glucopyranoside), Platycodigenin 3-O-glucopyranoside 28-methyl ester and Platycodigenin 3-O-glucopyranoside 28-methyl ester It is characterized by containing one or more saponin-based compounds among Platycodigenin 3-O-laminaribioside 28-methyl ester.
상기 제8단계에서 말토덱스트린을 첨가하는 것을 특징으로 한다.In the eighth step, maltodextrin is added.
상기 제2단계에서 상기 도라지 분말에 투입되는 용매의 부피는 상기 도라지 분말의 부피의 5배 내지 10배인 것을 특징으로 한다.In the second step, the volume of the solvent added to the bellflower root powder is 5 to 10 times the volume of the bellflower root powder.
상기 제2단계에서 투입되는 용매는 물 100%인 것을 특징으로 한다.The solvent introduced in the second step is characterized in that it is 100% water.
본 발명에 따르면 도라지 뿌리로부터 도라지 사포닌을 다량 함유한 추출물을 수득하고, 이 수득된 추출물로부터 2종 이상의 한외 여과막을 이용하여 여과를 함으로써 미생물학적으로 위생적이며, 특히 플라티코딘 D의 함유량을 증가시킨 도라지 사포닌을 농축 생산할 수 있는 효과가 있다.According to the present invention, an extract containing a large amount of bellflower saponin is obtained from bellflower roots, and the obtained extract is filtered using two or more types of ultrafiltration membranes, thereby making it microbiologically hygienic and especially increasing the content of platycodin D. It is effective in producing concentrated bellflower saponin.
도 1은 본 발명의 실시예에 따른 제조방법의 과정을 나타낸 순서도.
도 2a, 2b, 및 2c는 본 발명의 실시예에 따른 제조방법으로 제조된 추출물과 정제 농축 단계에서의 크로마토그램.1 is a flowchart showing the process of a manufacturing method according to an embodiment of the present invention.
Figures 2a, 2b, and 2c are chromatograms of the extract prepared by the production method according to an embodiment of the present invention and the purification and concentration step.
이하에서 도면을 참조하여 본 발명의 실시예에 따른 "도라지에서 추출된 도라지 사포닌 농축물을 함유하는 약학적 조성물의 제조방법"을 설명한다.Hereinafter, a “method for producing a pharmaceutical composition containing bellflower saponin concentrate extracted from bellflower root” according to an embodiment of the present invention will be described with reference to the drawings.
도 1은 본 발명의 실시예에 따른 제조방법의 과정을 나타낸 순서도이며, 도 2a, 2b, 및 2c는 본 발명의 실시예에 따른 제조방법으로 제조된 추출물과 정제 농축 단계에서의 크로마토그램이다.Figure 1 is a flow chart showing the process of the production method according to an embodiment of the present invention, and Figures 2a, 2b, and 2c are chromatograms of the extract prepared by the production method according to an embodiment of the present invention and the purification and concentration step.
본 발명에서 제조대상이 되는 "도라지에서 추출된 플라티코딘 D를 다량으로 함유하는 약학적 조성물"(이하, '조성물'이라 함)은 항염증, 항암효과, 통증완화효과, 소화효소분비, 콜레스테롤대사 개선효과, 간기능보호 및 개선효과, 면역기능조절활성, 뇌신경세포보호, 항비만, 항세포사멸 등 약리작용을 가지는 도라지 추출물이다.The "pharmaceutical composition containing a large amount of platycodin D extracted from bellflower root" (hereinafter referred to as 'composition'), which is the subject of manufacture in the present invention, has anti-inflammatory, anticancer effects, pain relieving effects, digestive enzyme secretion, and cholesterol. It is a bellflower extract that has pharmacological effects such as metabolic improvement effect, liver function protection and improvement effect, immune function regulation activity, brain nerve cell protection, anti-obesity, and anti-apoptosis.
이러한 목적을 가진 약리학적 효능을 갖는 조성물을 제조하기 위해서 본 발명에서는 물, 유기용매 또는 이들의 혼합물을 용매로 하여 도라지 뿌리로부터 도라지 추출물을 수득하고, 얻어진 도라지 추출물을 2종 이상의 한외여과막을 이용하여 고농도의 도라지 사포닌 농축물을 수득하고, 고농도 도라지 사포닌 농축물을 건강기능식품 또는 약학적 조성물로서 용이하게 사용할 수 있도록 건조하여 분말로 제조하는 공정을 사용한다. 이러한 공정을 사용하여 고농도의 도라지 사포닌 화합물을 대량으로 추출하여 농축 및 건조하는 생산 방법을 제공한다.In order to prepare a composition with pharmacological efficacy for this purpose, in the present invention, a bellflower extract is obtained from bellflower roots using water, an organic solvent, or a mixture thereof as a solvent, and the obtained bellflower extract is filtered using two or more types of ultrafiltration membranes. A process is used to obtain a high-concentration bellflower saponin concentrate and dry it into powder so that the high-concentration bellflower saponin concentrate can be easily used as a health functional food or pharmaceutical composition. Using this process, we provide a production method for extracting, concentrating, and drying large quantities of high-concentration bellflower saponin compounds.
이하에서는 도 1을 참조하여 본 발명의 조성물 제조방법을 설명한다.Hereinafter, the method for producing the composition of the present invention will be described with reference to FIG. 1.
먼저 건조된 도라지를 분쇄하여 분말 상태로 만든다.(102) 여기서 도라지 분말은 도라지 뿌리 전체 또는 코르크 층으로 형성된 피층을 분리한 후 얇게 썰어 건조한 것을 사용하는 것이 바람직하다. 분말 상태의 도라지를 사용하는 경우, 추출시 용출되는 함량이 증가되는 장점이 있다.First, the dried bellflower root is pulverized into powder. (102) Here, it is preferable to use the whole bellflower root or the skin layer formed by the cork layer, sliced and dried as the whole bellflower root. When using bellflower root in powder form, there is an advantage that the content eluted during extraction is increased.
다음으로, 준비된 도라지 분말에 용매(물, 유기용매, 이의 혼합물 중의 하나)를 투입한다.(S104) 유기용매로는 메탄올, 에탄올, 부탄올 등의 탄소수 1 내지 4의 저급 알코올이 사용될 수 있는데, 5% 내지 100% 농도의 용액을 사용한다. 도라지 분말의 내부에 포함된 물질이 용매의 내부로 추출되는데, 본 발명에서는 이를 도라지 추출물 이라고 정의한다.Next, a solvent (water, an organic solvent, or a mixture thereof) is added to the prepared bellflower root. (S104) As the organic solvent, a lower alcohol with 1 to 4 carbon atoms such as methanol, ethanol, or butanol can be used. Use solutions of % to 100% concentration. The substances contained inside the bellflower root powder are extracted into the solvent, and in the present invention, this is defined as bellflower root extract.
용매는 건조된 도라지 분말의 1배 내지 30배 부피량(w.v%), 바람직하게는 5배 내지 10배 부피량(w.v%)을 가한다. 도라지 분말과 용매의 혼합물을 10℃ 내지 90℃의 온도, 바람직하게는 50℃의 온도에서 추출이 이루어지도록 한다. 또한 1시간 내지 24시간 동안, 바람직하게는 6시간 내지 24시간 동안 냉침 추출, 열수 추출, 초음파 추출, 환류 추출, 가열 추출법 중 어느 하나의 추출방법으로 1회 내지 5회에 걸쳐서 추출한다. 바람직하게는 50℃의 온도에서의 추출로 1회 내지 3회 추출한다.The solvent is added in an amount of 1 to 30 times the volume (w.v%) of the dried balloon flower powder, preferably 5 to 10 times the volume (w.v%). The mixture of bellflower root powder and solvent is extracted at a temperature of 10°C to 90°C, preferably 50°C. In addition, extraction is performed 1 to 5 times for 1 to 24 hours, preferably 6 to 24 hours, using any one of cold extraction, hot water extraction, ultrasonic extraction, reflux extraction, and heat extraction. Preferably, extraction is performed 1 to 3 times at a temperature of 50°C.
위의 과정으로 얻어진 도라지 추출물을 냉각시킨다.(S106)Cool the bellflower extract obtained through the above process. (S106)
이와 같은 과정으로 만들어진 도라지 추출물의 90% 이상은 분자량 1,000 이하의 저분자당(1당~5당)이다. 그리고 도라지 추출물 고형분의 2% 이하가 도라지 사포닌이며, 이중 플라티코딘 D는 도라지 추출물 고형분의 0.65%를 넘지 못한다. 따라서 이러한 약리 효능을 가지고 있지 않은 저분자당을 제거하고 약리 효능을 가진 도라지 사포닌을 농축할 필요가 있다.More than 90% of bellflower extract made through this process is low molecular sugar (1 to 5 sugars) with a molecular weight of 1,000 or less. Also, less than 2% of the solid content of bellflower extract is bellflower saponin, of which platycodin D does not exceed 0.65% of the solid content of bellflower extract. Therefore, it is necessary to remove low molecular sugars that do not have pharmacological efficacy and concentrate bellflower saponins that have pharmacological efficacy.
도라지 추출물 내에 존재할 수 있는 소량의 식물 세포벽 성분이나 셀룰로오스(cellulose) 등의 불용성 물질의 제거를 위하여 공극의 크기가 1㎛ 정도인 마이크로필터를 이용하여 필터링한다.(S108)In order to remove small amounts of insoluble substances such as plant cell wall components or cellulose that may be present in the bellflower extract, it is filtered using a microfilter with a pore size of about 1㎛ (S108).
다음으로, 불용성 물질이 제거된 도라지 추출물을 한외여과막을 투과시켜 존재가능한 미생물과 불용성 물질, 거대분자 및 저분자당과 물을 제거하면서 농축한다. 바람직하게는 도라지 사포닌의 분자량 특성을 이용하여 분자량 한계가 20,000이상인 제1 한외 여과막을 투과하여 도라지 추출물내에 존재하는 위해할 수 있는 미생물과 불용성 물질 및 거대 분자를 제거한 여액을 얻는다.(S110)Next, the bellflower extract from which insoluble substances have been removed is passed through an ultrafiltration membrane and concentrated while removing possible microorganisms, insoluble substances, macromolecules, low-molecular sugars, and water. Preferably, by using the molecular weight characteristics of bellflower saponin, the filtrate is obtained by removing potentially harmful microorganisms, insoluble substances, and macromolecules present in the bellflower extract by passing it through a first ultrafiltration membrane with a molecular weight limit of 20,000 or more (S110).
일반적으로 대부분의 미생물은 0.45㎛의 공극 크기(pore size)의 멤브레인(membrane)을 통과시키면 모두 제거된다. 따라서, 1차적으로 MWCO 20,000인 여과막을 통과하게 되면 모든 미생물은 제거되므로, 미생물에 의한 식품 위해 요소를 충분히 제거할 수 있다.In general, most microorganisms are removed when they pass through a membrane with a pore size of 0.45㎛. Therefore, when it first passes through a filtration membrane with a MWCO of 20,000, all microorganisms are removed, so it is possible to sufficiently remove food hazards caused by microorganisms.
MWCO 20,000은 생화학적인 면에서 제품의 품질의 변화 등을 일으킬수 있는 효소(많은 효소중에서 가장 작은 효소의 분자량은 15,000, 그외 효소 단백질은 분자량이 거의 대부분 50,000 이상에서 수십만에 이르는 거대 분자임)의 대부분을 제 거할 수 있는 공극 크기이다.MWCO 20,000 refers to most enzymes that can cause changes in product quality from a biochemical perspective (the smallest enzyme among many enzymes has a molecular weight of 15,000; other enzyme proteins are mostly macromolecules with molecular weights ranging from over 50,000 to hundreds of thousands). This is the size of the pores that can be removed.
따라서, MWCO 20,000인 한외 여과막을 통과시켜 여액을 사용한다는 것은 미생물과 불필요한 효소 단백질을 제거한다는 것을 의미한다. 또한, 불용성 물질 뿐만 아니라 분자량이 20,000 이상인 그외 거대 분자가 제거되므로, 목표로 하는 기능성분(본 발명에서는 Platycodin D가 기준임)의 상대적 농축 정도(순도)가 증가한다.Therefore, using the filtrate by passing it through an ultrafiltration membrane with a MWCO of 20,000 means removing microorganisms and unnecessary enzyme proteins. In addition, since not only insoluble substances but also other macromolecules with a molecular weight of 20,000 or more are removed, the relative degree of concentration (purity) of the target functional ingredient (in the present invention, Platycodin D is the standard) increases.
이는 1종의 한외 여과막을 사용하여 정제 농축하였을 때 가능한 농축 정제 정도의 한계를 2종의 여과막을 사용하여 더 높게 끌어 올리는 것이며, 3종 또는 4종 이상의 여과막을 사용할 필요없이 2종이라는 최소한의 여과막으로 공정을 단순화시키고 생산성을 향상시키는 효과를 얻을 수 있다.This is to raise the limit of the degree of concentration and purification possible when purifying and concentrating using one type of ultrafiltration membrane to a higher level by using two types of filtration membranes, and the minimum number of filtration membranes of two types is eliminated without the need to use three or four or more types of filtration membranes. This has the effect of simplifying the process and improving productivity.
따라서, 건강기능식품 등의 제품의 제형화시에 사용될 수 있는 도라지 추출정제 농축물의 함유량을 기존보다 농축된 비율 만큼 적게(기능성분 섭취 함량을 기존과 동일하게 한다는 전제 조건일 경우) 사용할 수 있으며, 이를 통해 소비자의 1회 섭취량을 적게 하여 휴대 및 보관, 섭취가 기존보다 용이한 제품을 제조할 수 있게 된다.Therefore, the content of bellflower root extract purification concentrate that can be used when formulating products such as health functional foods can be used at a lower concentration ratio than before (if the precondition is that the intake content of functional ingredients is the same as before). Through this, it is possible to manufacture products that are easier to carry, store, and consume than before by reducing the consumer's one-time intake.
이 여액을 도라지 사포닌의 분자량 특성을 이용하여 분자량 한계가 1,000 이상인 제2 한외 여과막을 투과하여 도라지 추출물에 존재하는 불필요한 대부분의 단당류, 2당류, 3당류 등을 물 또는 용매 성분과 함께 제거한다. 제2 한외 여과막의 분자량 한계가 1,000 이상이기 때문에 도라지 추출물 농축물 내에 존재하는 도라지 사포닌 역시 분자량이 1,000 이상이 된다.(S112)Using the molecular weight characteristics of bellflower saponin, this filtrate is passed through a second ultrafiltration membrane with a molecular weight limit of 1,000 or more to remove most of the unnecessary monosaccharides, disaccharides, trisaccharides, etc. present in the bellflower extract along with water or solvent components. Since the molecular weight limit of the second ultrafiltration membrane is more than 1,000, the bellflower saponin present in the bellflower extract concentrate also has a molecular weight of more than 1,000. (S112)
분자량 1,000의 여과막을 사용하는 것은 여과막을 통과한 여액(분자량 1,000이하의 물질만 통과된 상태)은 버리고, 통과되지 못하고 계속 걸러져서 모인 잔류물(retentate)에는 분자량이 1,000이상인 모든 물질이 남는다.When using a filtration membrane with a molecular weight of 1,000, the filtrate that passed through the filtration membrane (only substances with a molecular weight of 1,000 or less passed through) is discarded, and all substances with a molecular weight of 1,000 or more remain in the retentate.
분자량 20,000의 여과막을 사용하는 것은 미생물 및 거대 분자를 제거하기 위하여 여과막을 통과한 여액(분자량 20,000 이하의 물질만 통과된 상태)을 모아 사용하는 것이며, 분자량 20,000의 여과막을 투과한 여액을 분자량 1,000의 여과막 비투과 농축물(retentate)로 농축한다.Using a filtration membrane with a molecular weight of 20,000 collects and uses the filtrate that has passed through the filtration membrane (only substances with a molecular weight of 20,000 or less have passed) to remove microorganisms and macromolecules. Concentrate to a retentate permeable through the filtration membrane.
그러므로, 분자량 1,000의 여과막 만을 사용하면 분자량 20,000이상의 거대분자 물질 모두와 미생물 등이 함께 여과막에 모이게 되므로, 농축 정제시 기능성분의 농축의 한계가 낮아 Platycodin D의 함량이 15mg/g DM 이상으로 농축되기가 어렵다.Therefore, if only a filtration membrane with a molecular weight of 1,000 is used, all macromolecular substances and microorganisms with a molecular weight of 20,000 or more will be collected together in the filtration membrane. Therefore, the limit of concentration of functional ingredients during concentration and purification is low, so the content of Platycodin D cannot be concentrated to more than 15 mg/g DM. It's difficult.
그러나 본 발명에서와 같이 2종의 여과막을 사용하게 되면, 분자량 20,000과 1,000사이의 물질만 제2 한외 여과막에 모이게 되므로 기능성분의 함량이 상대적으로 높아지게 되어 농축의 한계가 높아지며, Platycodin D의 함량이 22mg/g DM 이상으로도 농축이 가능하게 된다.However, when two types of filtration membranes are used as in the present invention, only substances with molecular weights between 20,000 and 1,000 are collected in the second ultrafiltration membrane, so the content of functional ingredients is relatively high, increasing the limit of concentration, and the content of Platycodin D is increased. Concentration is possible even above 22mg/g DM.
마이크로필터를 통과하면서 불용성 물질이 제거되고, 2종 이상의 한외 여과막을 통과하면서 미생물, 거대 분자, 저분자당 및 물이 제거된 상태를 도라지 사포닌 농축물이라고 정의한다.Insoluble substances are removed while passing through a microfilter, and microorganisms, macromolecules, low molecular sugars, and water are removed while passing through two or more types of ultrafiltration membranes, which is defined as bellflower saponin concentrate.
이와 같은 과정을 거친 도라지 사포닌 농축물에 포함된 사포닌계 화합물은 데아피오플라티코사이드 E(Deapioplatycoside E), 플라티코사이드 E(Platycoside E), 플라티코딘 D3(Platycodin D3), 폴리갈라신 D2(Polygalacin D2), 폴리갈라신 D(Polygalacin D), 플라티콘산 A(Platyconic acid A), 데아피오플라티코딘 D2(Deapioplatycodin D2), 플라티코딘 D2(Platycodin D2), 데아피오플라티코딘 D(Deapioplatycodin D), 플라티코딘 D(Platycodin D), 2"-O-아세틸-데아피오폴리갈라신 D2(2"-O-acetyl-deapiopolygalacin D2), 2"-O-아세틸-폴리갈라신 D2(2"-O-acetyl-polygalacin D2) 및 플라티콘산 A 메틸에스테르(Platyconic acid A methyl ester), 플라티코디게닌(Platycodigenin), 폴리갈라신산(Polygalacic acid), 플라티코게닌산 A 락톤(Platycogenic acid A lactone), 플라티코게닌산 A 락톤 3-O-글루코피라노사이드(Platycogenic acid A lactone 3-O-glucopyranoside), 플라티코디게닌 3-O-글루코피라노사이드 28-메틸에스테르(Platycodigenin 3-O-glucopyranoside 28-methyl ester) 및 플라티코디게닌 3-O-라미나리비오사이드 28-메틸에스테르(Platycodigenin 3-O-laminaribioside 28-methyl ester) 중의 하나 이상이다.The saponin compounds contained in bellflower saponin concentrate that went through this process are Deapioplatycoside E, Platycoside E, Platycodin D3, and Polygalacin D2 ( Polygalacin D2), Polygalacin D, Platyconic acid A, Deapioplatycodin D2, Platycodin D2, Deapioplatycodin D ( Deapioplatycodin D), Platycodin D, 2"-O-acetyl-deapiopolygalacin D2 (2"-O-acetyl-deapiopolygalacin D2), 2"-O-acetyl-polygalacin D2 ( 2"-O-acetyl-polygalacin D2) and Platyconic acid A methyl ester, Platycodigenin, Polygalacic acid, Platycogenic acid A lactone), Platycogenic acid A lactone 3-O-glucopyranoside, Platycodigenin 3-O-glucopyranoside 28-methyl ester (Platycodigenin 3- O-glucopyranoside 28-methyl ester) and one or more of Platycodigenin 3-O-laminaribioside 28-methyl ester.
다음 단계에서는 이와 같은 농축물을 감압 가열하면서 다시 한 번 농축과정을 거친다.(S114) 바람직하게는 60℃내지 80℃의 온도에서 농축하여 농축물의 당도(brix)를 10 내지 30이 되도록 하는 것이 바람직하며, 농축 과정에서 도라지 사포닌의 손실을 최소화하기 위하여 과도한 가열은 삼가는 것이 좋다.In the next step, the concentrate is concentrated again while heating under reduced pressure. (S114) Preferably, the concentrate is concentrated at a temperature of 60°C to 80°C so that the sweetness (brix) of the concentrate is 10 to 30. In order to minimize the loss of bellflower saponin during the concentration process, it is recommended to avoid excessive heating.
마지막으로 도라지 사포닌 농축물을 건강기능식품 또는 약학적 조성물로써 용이하게 사용할 수 있도록 분말상태로 만든다.(S116)Finally, bellflower saponin concentrate is powdered so that it can be easily used as a health functional food or pharmaceutical composition (S116).
건조하기에 최적의 농도로 농축된 도라지 사포닌 농축물은 분무 건조 또는 동결 건조 등의 방법을 통하여 용이하게 수분을 제거할 수 있다. 또한, 고농도로 농축된 도라지 사포닌 농축물은 건조 상태 및 보관이 용이하게 하기 위하여 적당량의 말토덱스트린 등을 혼합하여 건조될 수 있다. Bellflower saponin concentrate concentrated to the optimal concentration for drying can easily remove moisture through methods such as spray drying or freeze drying. In addition, the highly concentrated bellflower saponin concentrate can be dried by mixing an appropriate amount of maltodextrin, etc. to facilitate drying and storage.
분무 건조시에 말토덱스트린을 첨가하면 끈적임이 감소하고, 분무건조시의 수율이 증가(분무건조기 내에 늘어붙는 성분이 감소됨)한다. 또한, 건조 후의 분말의 성상이 말토덱스트린을 섞지 않은 경우보다는 보송보송한 상태로 이루어지기 때문에 보관 및 2차 가공이 용이해지는 장점이 있다.Adding maltodextrin during spray drying reduces stickiness and increases yield during spray drying (reduces components sticking in the spray dryer). In addition, since the powder after drying is in a fluffier state than when maltodextrin is not mixed, it has the advantage of making storage and secondary processing easier.
이와 같은 과정을 통해 도라치 추출물이 분말로 제조되어 건강기능식품 또는 약학적 조성물의 원료로써 용이하게 사용될 수 있다.Through this process, Dorachi extract is manufactured into powder and can be easily used as a raw material for health functional foods or pharmaceutical compositions.
이하에서는 전술한 과정을 통해 제조된 도라지 사포닌으로부터 플라티코딘 D를 다량으로 추출하여 약학적 조성물을 제조한 실시예를 설명한다.Hereinafter, an example in which a pharmaceutical composition was prepared by extracting a large amount of platycodin D from bellflower saponin prepared through the above-described process will be described.
참고예1 : HPLC(High Performance Liquid Chromatography) 분석Reference Example 1: HPLC (High Performance Liquid Chromatography) analysis
도라지 사포닌의 성분을 확인하기 위한 HPLC에는 펌프와 자동주입기, UV 검출기(Jasco, Japan)를 사용하였으며, 분석 방법은 다음과 같다.A pump, automatic injector, and UV detector (Jasco, Japan) were used in HPLC to confirm the components of bellflower saponin, and the analysis method was as follows.
참고 문헌 : 길경함유 Platycodin D의 분리 및 분석, 김영학, 강원대학교 산업과학대학원 생약자원개발학과 생약자원개발학전공, 석사학위 논문, 2013References: Isolation and analysis of Platycodin D containing gilgyeong, Younghak Kim, Kangwon National University Graduate School of Industrial Sciences, Department of Herbal Medicine Resources Development, Master's thesis, 2013
표 1의 조건으로 Platycodin D 함량 측정Measurement of Platycodin D content under the conditions in Table 1
0 min : 20% B, 20min :35% B, 30min : 50% B 31 min :20% B, 42min : 20% BMobile Phase: Solvent A: Water, Solvent B: Acetonitrile
0 min : 20% B, 20min :35% B, 30min : 50% B 31 min :20% B, 42min : 20% B
실시예1 : 도라지 추출물의 제조Example 1: Preparation of bellflower extract
도라지 분말 100g에 증류수 1,000㎖를 가하고, 50℃에서 8시간 동안 1회 추출한 후 냉각시켜 도라지 추출물을 얻었다.1,000 ml of distilled water was added to 100 g of bellflower root powder, extracted once at 50°C for 8 hours, and then cooled to obtain bellflower root extract.
또한 도라지 분말 100g에 유기용매(에탄올)와 물을 단계적으로 혼합하여 각각 1,000㎖가 되도록 가하고, 수욕상에서 8시간 동안 1회 추출한 후 냉각시켜 도라지 추출물을 얻었다. 본 발명에서는 유기용매를 20%에서 100%까지 20% 단위로 증가시키면서 시료를 제조하였다.In addition, 100 g of bellflower root powder was mixed with an organic solvent (ethanol) and water in stages to make 1,000 ml each, extracted once for 8 hours in a water bath, and then cooled to obtain bellflower extract. In the present invention, samples were prepared by increasing the organic solvent from 20% to 100% in 20% increments.
여기서 도라지 분말은 도라지 뿌리를 얇게 썰어 건조한 것으로 사용하였으며, 추출시 용출되는 함량을 증가시키기 위하여 분말로 하여 추출하였으며, 불용성 물질의 이행을 막기 위하여 추출포를 사용하여 1차 여과하여 추출액을 사용하였다.Here, the bellflower root was used as thinly sliced and dried bellflower root. It was powdered and extracted to increase the content eluted during extraction, and the extract was first filtered using an extraction cloth to prevent migration of insoluble substances.
각각의 도라지 추출물의 고형분 함량은 약 6brix 내외로 도라지 원물 고형분의 약 80%까지 최대 추출되었다. 이 때 도라지 사포닌의 지표성분인 플라티코딘 D의 함량은 표 2와 같다.The solid content of each bellflower extract was approximately 6 brix, and up to about 80% of the solid content of the original bellflower root was extracted. At this time, the content of platycodin D, an indicator component of bellflower saponin, is shown in Table 2.
실시예2 : 한외여과막을 이용한 도라지 추출물로부터 도라지 사포닌 농축물의 제조Example 2: Preparation of bellflower saponin concentrate from bellflower extract using ultrafiltration membrane
상기 실시예1에서 얻은 도라지 추출물 중 가장 함량이 많았던 시료 PGE-6으로서, 물 100%를 용매로 사용한 경우임을 확인하였다. 시료 PGE-6의 추출에서는 도라지로부터 고형분의 약 80%까지 추출되었으나, 이 추출물에는 90% 이상이 분자량 1,000 이하의 저분자당(1당~5당)이다. 이러한 저분자당을 제거하고, 불용성 물질과 물을 제거하기 위해 마이크로필터와 2종 이상의 한외여과막(MWCO 20,000 및 1,000)을 사용하여 도라지 추출물을 농축하였다.Among the bellflower extracts obtained in Example 1, sample PGE-6 had the highest content, and it was confirmed that 100% water was used as a solvent. In the extraction of sample PGE-6, about 80% of the solid content was extracted from bellflower root, but more than 90% of this extract is low molecular sugar (1 to 5 sugars) with a molecular weight of 1,000 or less. To remove these low molecular sugars, insoluble substances and water, the bellflower extract was concentrated using a microfilter and two or more types of ultrafiltration membranes (MWCO 20,000 and 1,000).
농축된 결과는 아래의 표 3과 같다.The concentrated results are shown in Table 3 below.
표 3에서 나타내는 바와 같이, 플라티코딘 D가 약 2.5배 이상 농축되는 것을 확인할 수 있었으며, HPLC로 분석한 크로마토그램(도 2a, 2b, 2c, 참조)을 보면 그 외 다른 도라지 사포닌들도 마찬가지로 플라티코딘 D와 같은 양상으로 농축되는 것을 확인하였다. As shown in Table 3, it was confirmed that platycodin D was concentrated by about 2.5 times or more, and looking at the chromatogram analyzed by HPLC (see Figures 2a, 2b, and 2c), other bellflower saponins were also platycodin D. It was confirmed that it was concentrated in the same manner as Ticodin D.
도 2a는 용매 추출 후 농축 과정을 거치지 않은 상태에서 측정한 값이며, 도 2b는 MWCO 1,000인 한외 여과막 만을 사용 정제 농축한 분말을 측정한 값이며, 도 2c는 MWCO 20,000 및 MWCO 1,000 인 한외 여과막 2종을 순차적으로 사용 정제 농축한 분말을 측정한 값이다.Figure 2a is the value measured without going through the concentration process after solvent extraction, Figure 2b is the value measured for the powder purified and concentrated using only an ultrafiltration membrane with MWCO 1,000, and Figure 2c is the value measured with ultrafiltration membrane 2 with MWCO 20,000 and MWCO 1,000. This is a value measured by purifying and concentrating powder using the species sequentially.
MWCO가 1,000인 한외 여과기 만을 사용하여 농축하였을 경우보다는 MWCO가 20,000인 제1 한외 여과막을 1차 사용하고, 2차로 MWCO가 1,000인 제2 한외 여과막을 사용한 경우가 저분자 당류와 물이 제거될 뿐만 아니라 HPLC의 크로마토그램에서 보이는 바와 같이 retention time 2분대의 물질이 다량 제거되는 것을 확인하였고, Platycodin D의 농축 정도가 훨씬 높아진 것(약15mg/g Dm에서 약 22mg/g DM 으로)을 확인하였다.Compared to the case of concentration using only an ultrafiltration with a MWCO of 1,000, low molecular sugars and water are not only removed when a first ultrafiltration membrane with a MWCO of 20,000 is used first and a second ultrafiltration membrane with a MWCO of 1,000 is used secondarily. As shown in the HPLC chromatogram, it was confirmed that a large amount of material was removed at a retention time of 2 minutes, and the degree of concentration of Platycodin D was confirmed to be much higher (from about 15 mg/g Dm to about 22 mg/g DM).
실시예3 : 도라지 사포닌 농축물의 분무 건조Example 3: Spray drying of bellflower saponin concentrate
상기 실시예2에서 얻은 도라지 사포닌을 가열 감압 농축기에서 60℃이하에서 분무 건조하기 용이한 25brix로 농축한 다음, 분무 건조하였다. 이 분무 건조한 분말을 HPLC로 분석하여 농축 후 도라지 사포닌 농축물의 플라티코딘 D 함량과 당도로 비교해 본 결과 함량의 변화는 거의 없는 것으로 확인되었다. 도라지 사포닌은 트리테르페노이드(triterpenoid) 성분으로 당류가 결합된 형태로 존재하며, 이들 사포닌은 열에 비교적 안정하므로 동결 건조 또는 분무 건조의 방식으로 용이하게 분말화 될 수 있다. 이러한 산업장비를 활용한 실험을 반복하여 보았을 때, 최종 분말에서 플라티코딘 D의 함량을 1~3%(w/w)까지 농축된 것을 얻었다.Bellflower saponin obtained in Example 2 was concentrated to 25 brix, which is easy to spray dry at 60°C or lower, in a heated and reduced pressure concentrator, and then spray dried. This spray-dried powder was analyzed by HPLC and compared to the platycodin D content and sugar content of bellflower saponin concentrate after concentration, and it was confirmed that there was almost no change in content. Bellflower saponin is a triterpenoid component that exists in the form of sugars bound together. Since these saponins are relatively stable to heat, they can be easily powdered by freeze-drying or spray-drying. When the experiment using this industrial equipment was repeated, the final powder was obtained with the content of platycodin D concentrated to 1-3% (w/w).
상기 실시예에서 볼 수 있듯이 도라지로부터 약리 효능이 있는 도라지 사포닌을 효과적으로 추출 농축 및 분말화 할 수 있으며, 분말화 할 때 말토덱스트린 등을 적당량 혼합하여 건조하게 되면 건조 수율 향상 및 보존성이 향상되어 분말의 2차 가공시의 제형성이 향상될 수 있다.As can be seen from the above examples, bellflower saponin, which has pharmacological effects, can be effectively extracted, concentrated, and powdered from bellflower root. When powdered, an appropriate amount of maltodextrin, etc. is mixed and dried to improve the drying yield and preservability of the powder. Formulation during secondary processing can be improved.
이 분말화 한 농축물은 건강기능식품, 약학적 조성물에 필요한 충분한 효능을 나타낼 수 있는 농도(0.1중량% 내지 20중량%)로 농축이 가능하므로, 정제, capsule, 과립 등의 형태로 다양하게 제형화할 수 있다. 또한 소량 섭취로도 충분한 효능을 발휘할 수 있는 원료로써 활용할 수 있는 충분한 가치가 있으며, 상기의 방법으로 지속적이며 반복적인 방법으로 계속해서 제품을 생산할 수 있으므로 경제적으로 대량 생산이 가능한 방법을 확립하게 되었다.This powdered concentrate can be concentrated to a concentration (0.1% by weight to 20% by weight) that can exhibit sufficient efficacy for health functional foods and pharmaceutical compositions, so it can be formulated in various forms such as tablets, capsules, and granules. You can get angry. In addition, it has sufficient value to be used as a raw material that can demonstrate sufficient efficacy even when consumed in small amounts, and since products can be continuously produced in a continuous and repetitive manner using the above method, a method capable of economically mass production has been established.
이상 첨부된 도면을 참조하여 본 발명의 바람직한 실시예를 설명하였지만, 상술한 본 발명의 기술적 구성은 본 발명이 속하는 기술 분야의 당업자가 본 발명의 그 기술적 사상이나 필수적 특징을 변경하지 않고서 다른 구체적인 형태로 실시될 수 있다는 것을 이해할 수 있을 것이다. 그러므로 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며 한정적인 것이 아닌 것으로서 이해되어야 하고, 본 발명의 범위는 상기 상세한 설명보다는 후술하는 특허청구범위에 의하여 나타내어지며, 특허청구범위의 의미 및 범위 그리고 그 등가 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.Although the preferred embodiments of the present invention have been described with reference to the accompanying drawings, the technical configuration of the present invention described above can be changed to other specific forms by those skilled in the art without changing the technical idea or essential features of the present invention. You will be able to understand that this can be implemented. Therefore, the embodiments described above should be understood in all respects as illustrative and not restrictive, and the scope of the present invention is indicated by the claims described later rather than the detailed description above, and the meaning and scope of the claims and All changes or modified forms derived from the equivalent concept should be construed as falling within the scope of the present invention.
Claims (5)
도라지 분말에 물, 유기용매, 물과 유기용매의 혼합물 중 어느 하나로 이루어진 용매를 투입하여 10℃ 내지 90℃의 온도에서 6시간 내지 24시간 동안 1회 내지 5회에 걸쳐서 도라지 추출물을 생성하는 제2단계와;
상기 도라지 추출물을 냉각시키는 제3단계와;
상기 도라지 추출물을 공극의 크기가 1㎛인 마이크로필터를 통과시켜 불용성 물질을 제거하는 제4단계와;
상기 불용성 물질이 제거된 도라지 추출물을 분자량 한계가 20,000 이상인 제1 한외 여과막을 통과시켜 미생물 및 거대 분자를 제거하는 제5단계와;
상기 미생물과 거대분자가 제거된 추출물을 분자량 한계가 1,000 이상인 제2 한외 여과막을 통과시켜 저분자물질과 물을 제거하여 도라지 사포닌 농축물을 생성하는 제6단계와;
상기 도라지 사포닌 농축물을 60℃ 내지 80℃의 범위에서 감압 가열하여 농축시키는 제7단계와;
상기 도라지 사포닌 농축물을 건조하여 분말로 만들고, 상기 분말에 말토덱스트린을 첨가하고, 상기 분말이 함유된 약학적 조성물을 제조하는 제8단계;를 포함하며,
상기 제2단계에서 상기 도라지 분말에 투입되는 용매의 부피는 상기 도라지 분말의 부피의 5배 내지 10배인 것을 특징으로 하는, 도라지에서 추출된 도라지 사포닌 농축물을 함유하는 약학적 조성물의 제조방법.A method for producing a pharmaceutical composition containing bellflower saponin concentrate, comprising: a first step of preparing a powder by drying and pulverizing the cork layer of the bellflower root;
A second process of producing a bellflower extract by adding a solvent consisting of water, an organic solvent, or a mixture of water and an organic solvent to bellflower root powder one to five times for 6 to 24 hours at a temperature of 10°C to 90°C. Steps and;
A third step of cooling the bellflower extract;
A fourth step of removing insoluble substances by passing the bellflower extract through a microfilter with a pore size of 1㎛;
A fifth step of removing microorganisms and macromolecules by passing the bellflower extract from which the insoluble substances have been removed through a first ultrafiltration membrane with a molecular weight limit of 20,000 or more;
A sixth step of passing the extract from which the microorganisms and macromolecules have been removed through a second ultrafiltration membrane with a molecular weight limit of 1,000 or more to remove low molecular substances and water to produce a bellflower saponin concentrate;
A seventh step of concentrating the bellflower saponin concentrate by heating it under reduced pressure in the range of 60°C to 80°C;
An eighth step of drying the bellflower saponin concentrate into powder, adding maltodextrin to the powder, and preparing a pharmaceutical composition containing the powder,
A method for producing a pharmaceutical composition containing bellflower saponin concentrate extracted from bellflower root, characterized in that the volume of the solvent added to the bellflower root powder in the second step is 5 to 10 times the volume of the bellflower root powder.
상기 도라지 사포닌 농축물에는 데아피오플라티코사이드 E(Deapioplatycoside E), 플라티코사이드 E(Platycoside E), 플라티코딘 D3(Platycodin D3), 폴리갈라신 D2(Polygalacin D2), 폴리갈라신 D(Polygalacin D), 플라티콘산 A(Platyconic acid A), 데아피오플라티코딘 D2(Deapioplatycodin D2), 플라티코딘 D2(Platycodin D2), 데아피오플라티코딘 D(Deapioplatycodin D), 플라티코딘 D(Platycodin D), 2"-O-아세틸-데아피오폴리갈라신 D2(2"-O-acetyl-deapiopolygalacin D2), 2"-O-아세틸-폴리갈라신 D2(2"-O-acetyl-polygalacin D2) 및 플라티콘산 A 메틸에스테르(Platyconic acid A methyl ester), 플라티코디게닌(Platycodigenin), 폴리갈라신산(Polygalacic acid), 플라티코게닌산 A 락톤(Platycogenic acid A lactone), 플라티코게닌산 A 락톤 3-O-글루코피라노사이드(Platycogenic acid A lactone 3-O-glucopyranoside), 플라티코디게닌 3-O-글루코피라노사이드 28-메틸에스테르(Platycodigenin 3-O-glucopyranoside 28-methyl ester) 및 플라티코디게닌 3-O-라미나리비오사이드 28-메틸에스테르(Platycodigenin 3-O-laminaribioside 28-methyl ester) 중의 하나 이상의 사포닌계 화합물이 함유되는 것을 특징으로 하는, 도라지에서 추출된 도라지 사포닌 농축물을 함유하는 약학적 조성물의 제조방법.According to paragraph 1,
The bellflower saponin concentrate includes Deapioplatycoside E, Platycoside E, Platycodin D3, Polygalacin D2, and Polygalacin D. D), Platyconic acid A, Deapioplatycodin D2, Platycodin D2, Deapioplatycodin D, Platycodin D D), 2"-O-acetyl-deapiopolygalacin D2 (2"-O-acetyl-deapiopolygalacin D2), 2"-O-acetyl-polygalacin D2 (2"-O-acetyl-polygalacin D2) and Platyconic acid A methyl ester, Platycodigenin, Polygalacic acid, Platycogenic acid A lactone, Platycogenic acid A lactone. 3-O-glucopyranoside (Platycogenic acid A lactone 3-O-glucopyranoside), Platycodigenin 3-O-glucopyranoside 28-methyl ester and Platycodigenin 3-O-glucopyranoside 28-methyl ester Bellflower saponin concentrate extracted from Bellflower, characterized in that it contains one or more saponin-based compounds among Platycodigenin 3-O-laminaribioside 28-methyl ester. Method for producing a pharmaceutical composition containing
상기 제2단계에서 투입되는 용매는 물 100%인 것을 특징으로 하는, 도라지에서 추출된 도라지 사포닌 농축물을 함유하는 약학적 조성물의 제조방법.According to paragraph 1,
A method for producing a pharmaceutical composition containing bellflower saponin concentrate extracted from bellflower root, characterized in that the solvent introduced in the second step is 100% water.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020230036774A KR102611611B1 (en) | 2023-03-21 | 2023-03-21 | Pharmaceutical composition containing platycodin D extracted from Platycodon grandiflorum and a method of producting thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020230036774A KR102611611B1 (en) | 2023-03-21 | 2023-03-21 | Pharmaceutical composition containing platycodin D extracted from Platycodon grandiflorum and a method of producting thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR102611611B1 true KR102611611B1 (en) | 2023-12-11 |
Family
ID=89162858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020230036774A KR102611611B1 (en) | 2023-03-21 | 2023-03-21 | Pharmaceutical composition containing platycodin D extracted from Platycodon grandiflorum and a method of producting thereof |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102611611B1 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100069202A (en) | 2008-12-16 | 2010-06-24 | 서울대학교산학협력단 | Compositions for prevention or treatment of bone diseases comprising platycodin d |
| KR20100086923A (en) | 2009-01-23 | 2010-08-02 | (주) 비엔씨바이오팜 | Pharmaceutical composition for preventing or treating hepatitis c, comprising extract of platycodon grandiflorum or platycodon grandiflorum saponin compound |
| KR20110061976A (en) | 2009-12-02 | 2011-06-10 | 한국화학연구원 | Pharmaceutical composition for preventing or treating myocardial infarction containing the membrane-separated extracts of platycodon grandiflorum as an active ingredient |
| KR20170117932A (en) | 2017-09-28 | 2017-10-24 | 두산중공업 주식회사 | Filtering Apparatus Containing Floating Media and Filtering Method |
-
2023
- 2023-03-21 KR KR1020230036774A patent/KR102611611B1/en active IP Right Grant
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100069202A (en) | 2008-12-16 | 2010-06-24 | 서울대학교산학협력단 | Compositions for prevention or treatment of bone diseases comprising platycodin d |
| KR20100086923A (en) | 2009-01-23 | 2010-08-02 | (주) 비엔씨바이오팜 | Pharmaceutical composition for preventing or treating hepatitis c, comprising extract of platycodon grandiflorum or platycodon grandiflorum saponin compound |
| JP2012515773A (en) * | 2009-01-23 | 2012-07-12 | ビー アンド シー バイオファーマ シーオー．，エルティーディ | Pharmaceutical composition for prevention or treatment of hepatitis C, comprising a kyokyo extract or a kyo saponin compound |
| KR20110061976A (en) | 2009-12-02 | 2011-06-10 | 한국화학연구원 | Pharmaceutical composition for preventing or treating myocardial infarction containing the membrane-separated extracts of platycodon grandiflorum as an active ingredient |
| KR20170117932A (en) | 2017-09-28 | 2017-10-24 | 두산중공업 주식회사 | Filtering Apparatus Containing Floating Media and Filtering Method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101488208B1 (en) | Burdock Fruit Extract Containing Arctigenin at High Content and Process for Producing Same | |
| US20210138010A1 (en) | Whole ginseng composition using ginseng roots, leaves and berries and method of preparing the same | |
| CN113425757A (en) | Dandelion extract and preparation method and application thereof | |
| KR101341755B1 (en) | The effective isolation method of panaxadiol saponin fraction from ginseng using pectinase | |
| Peng et al. | Changes in levels of phenylethanoid glycosides, antioxidant activity, and other quality traits in Cistanche deserticola slices by steam processing | |
| KR101880934B1 (en) | Pharmaceutical composition containing platycodin D extracted from Platycodon grandiflorum and a method of producting thereof | |
| KR102150162B1 (en) | Liquid composition for stick-type container comprising active mountain-cultivated ginseng extract having increased ginsenosides of human body absorption type, and preparation method thereof | |
| KR100517899B1 (en) | Bioconversion ginseng composite using microorganism and fabrication method thereof | |
| CN109293509A (en) | A method of preparing high-purity chlorogenic acid from bamboo extractive | |
| CN101755953A (en) | Green tea extract with blood sugar reducing effect and preparation method thereof | |
| CN111304272B (en) | Method for preparing rare ginsenoside from caulis et folium Notoginseng saponin converted from Fusarium verticillatum | |
| KR102611611B1 (en) | Pharmaceutical composition containing platycodin D extracted from Platycodon grandiflorum and a method of producting thereof | |
| CN106690244B (en) | Preparation and application of novel sweet gynostemma pentaphylla sweetener | |
| KR102115669B1 (en) | Preparation method of black Platycodon grandiflorus having increased crude saponin and reduced Platycodin D, inhibiting production of benzopyrene | |
| CN114588225B (en) | Extraction and conversion method of saponin in longhairy antenoron herb | |
| KR101960037B1 (en) | Method for producing stick type red ginseng product comprising red ginseng mixed concentrate | |
| CN113171397A (en) | Hangover alleviating traditional Chinese medicine composition for activating acetaldehyde dehydrogenase and preparation method thereof | |
| KR20100076524A (en) | Functional ginseng preparation using almond extract and process for thereof | |
| KR101958439B1 (en) | Method for producing Hovenia dulcis beverage product comprising Hovenia dulcis mixed concentrate | |
| KR20040067022A (en) | A process of extracting glabridine from licorice root | |
| KR101733048B1 (en) | Improving Vascular Disorder Related Cholesterol Metabolism Food Composition Containing Solidago Virgaurea Extract and Method for Preparing the Same | |
| KR20100116919A (en) | Compositions comprising extract from codonopsis lanceolata for preventing or treating obesity, hyperlipidemia or fatty liver | |
| KR20100093306A (en) | Method for manufacturing the ginseng extrat having the reduced gineng flavor and bitter taste | |
| KR101734022B1 (en) | Method of preparing combined extract powder of fermented scutellariae radix and gastrodiae rhizoma from compounding solution of micro-organism and natural enzyne | |
| CN112794812B (en) | Alkaloid compound extracted from banana flower and extraction method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GRNT | Written decision to grant |